ZA202307921B - Combination of raf inhibitor and mek inhibitor - Google Patents
Combination of raf inhibitor and mek inhibitorInfo
- Publication number
- ZA202307921B ZA202307921B ZA2023/07921A ZA202307921A ZA202307921B ZA 202307921 B ZA202307921 B ZA 202307921B ZA 2023/07921 A ZA2023/07921 A ZA 2023/07921A ZA 202307921 A ZA202307921 A ZA 202307921A ZA 202307921 B ZA202307921 B ZA 202307921B
- Authority
- ZA
- South Africa
- Prior art keywords
- cancer
- inhibitor
- subject
- treating
- raf
- Prior art date
Links
- 229940124647 MEK inhibitor Drugs 0.000 title abstract 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 5
- 229940126062 Compound A Drugs 0.000 abstract 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 2
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 102000007530 Neurofibromin 1 Human genes 0.000 abstract 1
- 108010085793 Neurofibromin 1 Proteins 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 230000037442 genomic alteration Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163151425P | 2021-02-19 | 2021-02-19 | |
| US202163173158P | 2021-04-09 | 2021-04-09 | |
| PCT/US2022/016962 WO2022178244A1 (en) | 2021-02-19 | 2022-02-18 | Combination of raf inhibitor and mek inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202307921B true ZA202307921B (en) | 2024-04-24 |
Family
ID=82931723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/07921A ZA202307921B (en) | 2021-02-19 | 2023-08-15 | Combination of raf inhibitor and mek inhibitor |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240058338A1 (enExample) |
| EP (1) | EP4294400A4 (enExample) |
| JP (1) | JP2024507221A (enExample) |
| KR (1) | KR20230147136A (enExample) |
| AU (1) | AU2022223437A1 (enExample) |
| CA (1) | CA3211167A1 (enExample) |
| IL (1) | IL305250A (enExample) |
| MX (1) | MX2023009642A (enExample) |
| WO (1) | WO2022178244A1 (enExample) |
| ZA (1) | ZA202307921B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240390373A1 (en) * | 2021-10-01 | 2024-11-28 | Day One Biopharmaceuticals, Inc. | Raf kinase inhibitors for treating tumors harboring gene fusions |
| CN122555562A (zh) * | 2023-11-15 | 2026-08-11 | 首日生物制药公司 | 治疗儿科低级别胶质瘤的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013144923A1 (en) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| BR112016014481B1 (pt) * | 2013-12-20 | 2022-11-08 | Biomed Valley Discoveries, Inc | Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit |
| UY36046A (es) * | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| WO2016025648A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a raf inhibitor and related methods |
| KR102811888B1 (ko) * | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
-
2022
- 2022-02-18 CA CA3211167A patent/CA3211167A1/en active Pending
- 2022-02-18 EP EP22756995.1A patent/EP4294400A4/en active Pending
- 2022-02-18 JP JP2023550043A patent/JP2024507221A/ja active Pending
- 2022-02-18 IL IL305250A patent/IL305250A/en unknown
- 2022-02-18 MX MX2023009642A patent/MX2023009642A/es unknown
- 2022-02-18 WO PCT/US2022/016962 patent/WO2022178244A1/en not_active Ceased
- 2022-02-18 AU AU2022223437A patent/AU2022223437A1/en not_active Abandoned
- 2022-02-18 KR KR1020237031421A patent/KR20230147136A/ko active Pending
-
2023
- 2023-08-15 ZA ZA2023/07921A patent/ZA202307921B/en unknown
- 2023-08-16 US US18/450,638 patent/US20240058338A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023009642A (es) | 2023-10-16 |
| AU2022223437A1 (en) | 2023-09-07 |
| EP4294400A4 (en) | 2025-01-01 |
| CA3211167A1 (en) | 2022-08-25 |
| US20240058338A1 (en) | 2024-02-22 |
| KR20230147136A (ko) | 2023-10-20 |
| JP2024507221A (ja) | 2024-02-16 |
| EP4294400A1 (en) | 2023-12-27 |
| IL305250A (en) | 2023-10-01 |
| WO2022178244A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20250258A1 (ar) | مثبطات 2-آزا باي سيكلو هبتان kras | |
| Gustine et al. | Ibrutinib discontinuation in Waldenström macroglobulinemia: etiologies, outcomes, and IgM rebound | |
| ZA202310378B (en) | Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof | |
| JP2020533315A5 (enExample) | ||
| Pihlak et al. | Complementary medicine use among cancer patients receiving radiotherapy and chemotherapy: methods, sources of information and the need for counselling | |
| BR112021015098A2 (pt) | Inibidores de enpp1 e métodos de modulação da resposta imune | |
| BR112022010319A2 (pt) | Uso de bi853520 no tratamento de câncer | |
| MX2023009642A (es) | Combinacion de inhibidor de raf e inhibidor de mek. | |
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| AU2017261286A1 (en) | Treatment of hair loss disorders with deuterated JAK inhibitors | |
| MX2023012875A (es) | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| WO2022188898A3 (zh) | 化合物盐酸赛庚啶在制备预防或治疗非洲猪瘟药物中的应用 | |
| MX2022015800A (es) | Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular. | |
| WO2015095838A3 (en) | Cancer treatments using combinations of mek type i and erk inhibitors | |
| MX2025010157A (es) | Metodo de preparacion y uso de un derivado de dihidrotienopirimidina | |
| Foss et al. | Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma | |
| JOP20230090A1 (ar) | نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم | |
| Kundra et al. | Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
| O'Brien et al. | NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia | |
| SA523440403B1 (ar) | Magl مثبط | |
| Liu et al. | Dexmedetomidine as an adjuvant for patients undergoing breast cancer surgery: a meta-analysis | |
| MX2023005303A (es) | Inhibidor de raf para el tratamiento del glioma de bajo grado. |